Migration and Separation


Added on  2019-09-23

17 Pages9743 Words166 Views
Disease and DisordersBiology
AbstractDengue is transmitted to human through mosquito bites which makes it a vector-borne disease. Itis believed to be one of the most significant tropical and sub-tropical diseases, but because of urbanization, climate change, and international traveling, it is found to be scattered all over the world. Hence, it is necessarily required to control the scattering of Dengue virus and treatment ofdiseases caused by Dengue is also required. Dengue virus has to identify the cell surface receptors of the host with the help of virus-encoded protein envelope in order to infect the host. Therefore, recognition of virus receptor is very significant to understand the process of infection and in developing the anti-virals and vaccines. However, enough knowledge about Dengue receptors in human hosts and insects is not available. Characterization of all the assumed Denguereceptors has been done poorly. The project is aimed at identifying and characterizing the authentic Dengue receptor with the help of various stringent cellular and molecular techniques. We have become successful in knocking out a putative Dengue receptor from the cell line of mosquito by using a state-of-the art tool used for genome editing known as CRISPR. This is a very simple yet powerful and versatile tool used to silence certain genes present in the genome. CRISPR/Cas9 system in bacteria/Archaea was developed as a defense mechanism to fight phage (virus) infections. Nowadays, it is used as a tool to edit gene in numerous organisms for the whole lifetime.Dengue Fever:Dengue is an RNA virus that is single-stranded belonging to the genus of Flavivirus and to the family of Flaviviridae. In recent years, this mosquito-borne viral disease has spread rapidly in every region of WHO. Transmission of dengue virus is mainly through female mosquitoes from the species of Aedes aegypti and Ae. Ablopictus to a lesser extent. Infections such as yellow fever, chikungunya, and Zika are also transmitted by the same mosquito. Local variations such astemperature, rainfall, and unplanned rapid urbanization results in the widespread of Dengue in overall tropics.During Thailand and Philippines Dengue epidemics in the 1950s, first severe Dengue (Dengue Haemorrhagic Fever) was recognized. At present, severe Dengue has become the chief cause of hospitalization and death among the affected adults and children in the regions of Latin America and Asia.Dengue is caused by four closely related distinct serotypes of virus (DEN-1, DEN-2, DEN-3, andDEN-4). Recovery from the infection caused by one serotype ensures lifelong immunity against that particular serotype and partial or temporary cross-immunity against other serotypes. Following infections caused by other serotypes intensifies the risk of causing severe dengue.Lifecycle:Dengue virus is continuing its existence in urban lifecycle because it is being transferred from mosquito to humans and then back to mosquito from the human. Aedes aegypti mosquito is the primary vector of Dengue virus. However, Aedes albopictus may also transmit the virus (Brooks,Carroll, Butel, Morse, & Mietzner, 2010). Female mosquito feeding on viremic human results in
Migration and Separation_1

the transmission of Dengue virus from human to mosquito. The period of development lasts 8-12days within the mosquito, and it comprises of a systematic spread of the virus from the mid-gut. Once this period is over, the transmission of the virus to any human can again take place at any point of mosquito's remaining life (WHO, TDR, 2009).Global burden of dengue:A radical growth in the global incidence of dengue has been recorded in the recent decades. The actual number of cases of dengue either remains underreported and misclassified. As per a recentestimate, there are 390 million per year infections of dengue (95% reliable, in the interval of 284–528 million) out of which 96 million (67-136 million) are observed clinically (with some disease severity). 1 Another study about the existence of the virus suggests that 3.9 billion peoplefrom 128 countries have the threat of being infected by dengue virus. 2 The number of cases was2.2 million in 2010 and increased to 3.2 million in 2015 as reported by those members from 3 WHO regions who report their annual number of cases on a regular basis. Although the total burden of the disease all over the world is still uncertain, the activities commenced recording all the cases of dengue partially describes the steep increment in the number of testified cases in the current years.Other symptoms of the disease include its patterns that are epidemiological that include hyper-endemicity in various serotypes of dengue virus in various countries. Frightening effects on human health and national and global economies.Severe epidemics of dengue was experienced by 9 countries before 1970. The prevalence of the disease is found to be present in 100 or more countries from the WHO regions of the America, Africa, the Eastern Mediterranean, the Western Pacific, and South-East Asia. South-East Asia, America, and Western Pacific regions being affected most seriously.Over 1.2 million in 2008 and more than 3.2 million in 2015 cases across Americas, Western Pacific and South-East Asia were recorded (As per the official data recorded by member states). The number of cases in the record is noticed to be increasing recently. In America alone, there were 2.35 million reported cases in 2015, out of which 10 200 cases were treated as severe dengue which resulted in 1181 deaths.The spread of the disease is not only increasing the number of cases, but it is resulting in the occurrence of explosive outbreaks. Europe is now experiencing the threat of possible dengue fever outbreak as the first case of local transmission was reported in Croatia and France and 3 imported cases in some other European countries. In the year 2012, more than 2000 cases reported as a result of dengue outbreak on Madeira Islands of Portugal, and there were imported cases in the mainland of Portugal and 10 other nations of Europe. After malaria, dengue is found to be the second most diagnosed reason of fever among the travelers coming back from middle and low-income nations. Cases were recorded in Yunnan province of China and Florida (United States of America) in the year 2013. Some of the South American countries such as Costa Rica, Mexico, and Honduras arecontinuously being affected by Dengue. In Asia, the increase in cases of dengue after a gap of
Migration and Separation_2

some years was reported by Singapore and Laos has also suffered the outbreaks. As per the indications from the trends a rise in the number of cases in the Cook Islands, People’s Republic of China, Malaysia, Fiji, and Vanuatu in 2014. The same year, Pacific Island countries were also affected by Dengue Type 3 (DEN 3) after a gap of 10 years. Japan recorded the occurrence of Dengue after the gap of 70 years.In 2015, with more than 15000 cases in Delhi, India, was recorded as its worst outbreak after 2006. An outbreak of 181 cases was reported in The Hawaii Island, United States of America, in 2015 and the transmission continued in 2016. The countries of Pacific island such as Tonga, Fiji,and French Polynesia continued to record cases. Large dengue outbreaks were recorded throughout the world that characterized the year 2016. Over 2.38 million cases in some regions of the America were recorded in 2016, out of which Brazil alone added nearly 1.5 million cases, which was about 3 times higher than those recorded in 2014 where there were 1032 dengue deaths in the same region. Over 375 000 dengue cases were suspected in the Western Pacific Region in 2016, of which 176 411 cases were reported in the Philippines and 100 028 cases in Malaysia, both the countries demonstrated the similar condition in the previous year. An outbreak of over 7000 suspected cases was declared in the Solomon Islands. In Burkina Faso, Africa, a localized outbreak of 1061 probable cases of dengue was reported.In 2017 (as per Epidemiological Week 11), 50 172 dengue fever cases were recorded in the Region of America, a decline when compared with those in previous years. Some Member Statesof the Western Pacific region recorded dengue outbreaks and DENV-1 and DENV-2 serotypes circulation.Transmission:The mosquito Aedes aegypti acts as a primary vector for spreading dengue. The transmission of virus takes place from the bites of infected female mosquitoes to human. Once the virus incubation period of 4–10 days get over, an infected mosquito can transmit the virus for its remaining life. Symptomatic or asymptomatic infected humans are the primary carriers and result in multiplying the virus because for uninfected mosquitoes, they serve as the source for thevirus. Already infected dengue virus patients are capable of transmitting the infection (for 4–5 days; maximum 12) through Aedes mosquitoes after the first appearance of symptoms. Urban habitats serve as the livelihoods for Aedes aegypti mosquitoes and man-made containers as their breeding grounds. Ae. aegypti feeds in day-time unlike other mosquitoes; early morning and evening before the dusk are the peak times when its biting is most likely to occur. Multiple people are bitten by female Aedes aegypti in each of its feeding periods. Aedes albopictus, whichis considered the secondary vector of dengue in Asia, has been spread to North America and over25 countries of European Region, primarily through trading the used tires and other goods which act as a breeding habitat (e.g. lucky bamboo) internationally. Aedes albopictus is very adaptive which helps it to endure in Europe where regions are cooler temperate. Its adaptation to the temperatures below freezing, the ability to shelter in microhabitats, and hibernation are the main causes of its widespread.Manifestations:
Migration and Separation_3

Infections from Dengue virus can be manifested in different ways. Infected persons may be asymptomatic, or dengue hemorrhagic fever with or without shock syndrome of dengue (Table 1), or may have manifestations corresponding to that of typical dengue fever. WHO has divided the dengue illness course into 3 stages: febrile, critical, and recovery. Once 4-10 days of incubation period are over, the dengue fever is said to be at the beginning of the febrile phase. Patients suffer sudden inception of high-grade fever, and frequently patients suffer headaches, myalgias, retro-orbital pain, arthralgias, and facial flushing. Many complain of vomiting, nausea,and appetite loss. Injected pharynx, sore throat, and conjunctivitis are sometimes noted. There can be minor hemorrhagic manifestations such as petechiae, gingival and epistaxis bleeding and rare bleeding in gastro intestine and vagina. At this time, a person can suffer from hepatomegaly and a consistent decline in the count of white blood cells. This febrile phase lasts 2-7 days, and atthis stage, it is very difficult to determine which of the cases will end up severe dengue fever (WHO, 1997; WHO, TDR, 2009).The critical phase starts from 3 to 7 days, the temperature declines to 37.5-38°C or less and remains fixed. At this time, there can be a growth in capillary permeability resulting in a rise in hematocrit (WHO, TDR, 2009). Growth in plasma leakage and capillary permeability is assumedas dengue hemorrhagic fever (WHO, 1997). It is worth noting that before the occurrence of plasma leakage, consistent decline in the total count of WBCs and a rapid decline in the count of platelets. If capillary permeability increases, the condition of the patient improves and is assumed to suffer from dengue infection of non-severe type. The manifestation of anyone of the following is considered to be severe dengue: leakage of plasma with or without shock, severe organ impairment, or severe bleeding (WHO, TDR, 2009). An abdominal ultrasound or a chest X-ray can be used in recognizing severe dengue cases, as increased capillary permeability may lead to the development of ascites and pleural effusion (WHO, TDr, 2009). As verified by hematocrit elevation hemoconcentration will occur, In addition to leucopenia and thrombocytopenia shown by labs (WHO, 1997).Leakage of excessive amounts of plasma in the extravascular space leads to the occurrence of dengue shock syndrome. This normally occurs around day 4-5 or when the fever decreases (WHO, TDR, 2009). Patients will show symptoms of circulatory failure such as blotchy, cool, and edematous skin, tachycardia, circumoral cyanosis, a narrowing pulse pressure, and weak pulse (WHO, 1997). It is significant to note that there is a rise in diastolic blood pressure while systolic blood pressure does not change. This can be ignored if systolic blood pressure remains inthe normal range. Though the narrowing pulse pressure is a negative symptom of shock and the patient needs quick and ample care. Pulse pressure lesser than or equal to 20mm Hg is defined asthe shock (WHO, TDR, 2009). Treatment of shock results in recovery in 2-3 days (WHO, 1997).Multiple organ failure, disseminated intravascular coagulation, and metabolic acidosis are likely to occur if the identification of shock does not take place and aggressive treatment is not given. Severe hemorrhages and occurrence of death happen at last (WHO, TDR, 2009).If appropriate management and monitoring is done, the recovery phase that consists of extravascular fluid reabsorption starts within 48-72 hours. Improved symptoms show that the
Migration and Separation_4

End of preview

Want to access all the pages? Upload your documents or become a member.

Related Documents
Design a Short Primer Sequence for PCR Amplification

Detection and Characterization of Mono-allelic Knockout in C6/36 Cells

Characterization of Prohibitin-2 as a Dengue Virus Receptor

Diseases Ddrugs And Complications

Genetically modifying insects to inhibit disease transmission

Dengue Fever and Public Health Assignment